

Silvia Baroncelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3377680/publications.pdf>

Version: 2024-02-01

37
papers

823
citations

758635

12
h-index

500791

28
g-index

38
all docs

38
docs citations

38
times ranked

955
citing authors

#	ARTICLE	IF	CITATIONS
1	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. <i>Nature Medicine</i> , 1999, 5, 643-650.	15.2	288
2	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. <i>Molecular Therapy</i> , 2007, 15, 1716-1723.	3.7	79
3	Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. <i>Journal of General Virology</i> , 2004, 85, 1191-1201.	1.3	63
4	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. <i>Journal of Medical Primatology</i> , 2003, 29, 193-208.	0.3	51
5	<i>Macaca mulatta</i> , <i>Macaca fascicularis</i> and <i>Macaca nemestrina</i> in AIDS vaccine development. <i>Expert Review of Vaccines</i> , 2008, 7, 1419-1434.	2.0	45
6	Development and use of SIV-based Integrase defective lentiviral vector for immunization. <i>Vaccine</i> , 2009, 27, 4622-4629.	1.7	41
7	Antiretroviral Treatment in Pregnancy: A Six-Year Perspective on Recent Trends in Prescription Patterns, Viral Load Suppression, and Pregnancy Outcomes. <i>AIDS Patient Care and STDs</i> , 2009, 23, 513-520.	1.1	39
8	Single-nucleotide polymorphisms in human β -defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. <i>Aids</i> , 2008, 22, 1515-1517.	1.0	33
9	Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. <i>Retrovirology</i> , 2012, 9, 69.	0.9	21
10	Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. <i>Archives of Virology</i> , 2008, 153, 463-472.	0.9	18
11	Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. <i>Journal of Medical Virology</i> , 2011, 83, 551-556.	2.5	13
12	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. <i>Virology</i> , 2004, 324, 531-539.	1.1	12
13	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. <i>Journal of General Virology</i> , 2006, 87, 3385-3392.	1.3	11
14	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. <i>International Journal of STD and AIDS</i> , 2012, 23, 459-463.	0.5	10
15	Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1479-1485.	1.3	10
16	Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19. <i>Cells</i> , 2022, 11, 788.	1.8	10
17	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 71-77.	0.5	9
18	HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy. <i>Journal of Medical Virology</i> , 2016, 88, 2115-2124.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Characterization of α -Defensin Plasma Levels in Macaca Fascicularis and Correlations with Virological Parameters during SHIV89.6Pcy11 Experimental Infection. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 287-296.	0.5	6
20	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. <i>Infectious Diseases</i> , 2016, 48, 317-321.	1.4	6
21	Immune Activation and Microbial Translocation Markers in HIV-Exposed Uninfected Malawian Infants in the First Year of Life. <i>Journal of Tropical Pediatrics</i> , 2019, 65, 617-625.	0.7	6
22	Dynamics of immunoglobulin G subclasses during the first two years of life in Malawian infants born to HIV-positive mothers. <i>BMC Pediatrics</i> , 2020, 20, 181.	0.7	6
23	HIV-1 coreceptor switch during 2 years of structured treatment interruptions. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1565-1570.	1.3	4
24	Soluble CD14 levels in plasma and breastmilk of Malawian HIV+ women: Lack of association with morbidity and mortality in their exposed infants. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12812.	1.2	4
25	IgG abnormalities in HIV-positive Malawian women initiating antiretroviral therapy during pregnancy persist after 24 months of treatment. <i>International Journal of Infectious Diseases</i> , 2019, 88, 1-7.	1.5	4
26	Dried blood spots for the quantitative evaluation of IgG isotypes and correlation with serum samples in HIV-exposed uninfected (HEU) infants. <i>Journal of Immunological Methods</i> , 2021, 493, 113019.	0.6	4
27	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. <i>Virus Research</i> , 2007, 126, 86-95.	1.1	3
28	Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens. <i>Journal of Infection</i> , 2011, 63, 144-150.	1.7	3
29	Interindividual and Intra-Individual Variabilities of Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug Experienced HIV Patients Receiving Salvage Regimens. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 785-790.	1.0	3
30	Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi. <i>Medical Microbiology and Immunology</i> , 2018, 207, 175-182.	2.6	3
31	HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine. <i>AIDS Research and Therapy</i> , 2021, 18, 48.	0.7	3
32	Immunoglobulin G passive transfer from mothers to infants: total IgG, IgG subclasses and specific antipneumococcal IgG in 6-week Malawian infants exposed or unexposed to HIV. <i>BMC Infectious Diseases</i> , 2022, 22, 342.	1.3	3
33	Anti-Streptococcus pneumoniae and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. <i>Journal of Medical Microbiology</i> , 2015, 64, 795-797.	0.7	2
34	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2
35	Seroprevalence of Brucella Infection in a Cohort of HIV-Positive Malawian Pregnant Women Living in Urban Areas. <i>Vector-Borne and Zoonotic Diseases</i> , 2022, , .	0.6	1
36	Response to Segat et al. "Are DEFB1 gene polymorphisms associated with HIV-1 infection and virus replication?" <i>Aids</i> , 2009, 23, 649-650.	1.0	0

#	ARTICLE	IF	CITATIONS
37	Markers of microbial translocation during pregnancy: differences among HIV+ women of African and European provenance. <i>Journal of Infection in Developing Countries</i> , 2020, 14, 184-190.	0.5	0